PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery
Abstract
Patient-derived xenografts (PDXs) are tools of the trade for many researchers from all disciplines and medical specialties. Most endocrinologists, and especially those working in oncology, commonly use PDXs for preclinical drug testing and development, and over the last decade large collections of PDXs have emerged across all tumor streams. In this review, we examine how the field has evolved to include PDXs as versatile resources for research discoveries, providing evidence for guidelines and changes in clinical practice.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 12, 2020
- Source ID
- 10.1210/jendso/bvaa132
Entities
People
- Gail Petuna Risbridger
- Mitchell G Lawrence
- Renea A Taylor
Organizations
- Cass Foundation
- Monash University
- National Health and Medical Research Council
- Peter MacCallum Cancer Centre
- United States Department of Health and Human Services
- University of Melbourne